Assessing Erasca (ERAS) Valuation After Early Clinical Signals And Strong Share Price Momentum
Erasca (ERAS) is gaining attention due to early clinical signals for its drugs ERAS-0015 and ERAS-4001, and upcoming conference presentations. Despite significant share price momentum, the company's valuation, evidenced by a 10.7x price-to-book ratio, appears overvalued given its lack of meaningful revenue and ongoing net losses. Investors are prioritizing the potential of its RAS/MAPK focused pipeline over current financials, suggesting little room for error in future trial outcomes.
Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat
Erasca highlighted early clinical responses and pharmacokinetic advantages of its drug ERAS-0015 during a Guggenheim fireside chat, claiming a significant potency edge over competitors. The company reported multiple responses with ERAS-0015 in Phase 1 trials with good tolerability and intends to advance its pan-KRAS inhibitor ERAS-4001, planning future monotherapy and combination expansions. Erasca aims to differentiate its RAS-focused pipeline by optimizing both potency and pharmacokinetics to improve patient outcomes while managing toxicity.
Erasca stock reaches 52-week high at 12.48 USD
Erasca Inc.'s stock reached a new 52-week high of $12.48, reflecting a significant surge of 663.8% over the past year. Despite analysts not expecting profitability this year, the company's strong liquidity and focus on cancer therapies have garnered investor confidence. Recent events include a successful public offering and raised price targets from several analyst firms due to progress in its oncology pipeline.
ERAS: Early clinical data show promising efficacy and safety for next-generation pan-RAS and pan-KRAS inhibitors
Early clinical data for Erasca's pan-RAS and pan-KRAS inhibitors demonstrate promising efficacy and safety profiles, highlighted by differentiated potency, pharmacokinetics, and safety. The discussion from a recent biotech summit emphasized that upcoming data will guide dose expansion and combination strategies, particularly for major solid tumors. This information is based on a Guggenheim Securities Emerging Outlook: Biotech Summit 2026 audio transcript.
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target By Investing.com
Stifel has reiterated its Buy rating and $10 price target for Erasca Inc. (NASDAQ:ERAS) after a fireside chat with the company's CFO/CBO. Despite the stock trading above its price target and showing significant recent returns, the company remains unprofitable with a net income of -$127.69 million, though it has a strong balance sheet. Erasca's ERAS-0015 drug candidate is viewed as having a competitive advantage in the panRAS landscape, and the company recently completed a public offering to raise substantial gross proceeds.
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target
Stifel has reiterated its Buy rating and $10.00 price target for Erasca Inc (NASDAQ:ERAS) after a fireside chat with the company's CFO/CBO. The stock has seen significant returns recently, trading above the target price and near its 52-week high, despite the company remaining unprofitable. Erasca is positioned as a key player in the panRAS competitive landscape with its ERAS-0015 drug candidate, which is optimized for both PK and potency.
Erasca (ERAS) Is Up 15.2% After Upsized Offering Extends Cash Runway For RAS/MAPK Pipeline
Erasca (ERAS) saw its stock rise by 15.2% following an upsized public offering that raised approximately US$258.8 million, significantly extending its cash runway. This financing allows the clinical-stage oncology company to fund ongoing and planned trials for its RAS/MAPK pipeline, shifting the investment focus to clinical data quality and timelines rather than immediate bankruptcy concerns. Despite an inflated share price according to valuation reports, the extended cash runway has eased short-term dilution risk, while execution risk for its drug development remains.
Erasca to Present at Upcoming Conferences in February
Erasca, Inc. announced its management will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook: Biotech Summit and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. The company, focused on RAS/MAPK pathway-driven cancers, will hold fireside chats and one-on-one investor meetings at both events. Live audio webcasts and archived replays will be available on Erasca's website.
Erasca (NASDAQ:ERAS) Trading 6.4% Higher - Here's What Happened
Erasca (NASDAQ:ERAS) stock rose 6.4% to $11.96 on Thursday, with trading volume significantly lower than its average. Analysts hold a "Moderate Buy" consensus rating with a target price of $9.22, and several recently raised price objectives. Insider selling by General Counsel Ebun Garner was noted, while institutional ownership stands at approximately 67.8%.
Erasca to Present at Upcoming Conferences in February
Erasca, Inc., a clinical-stage precision oncology company, announced its participation in two investor conferences in February 2026. Management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Live audio webcasts and replays of these events will be available on the company's website.
Short Interest in Erasca, Inc. (NASDAQ:ERAS) Expands By 30.0%
Short interest in Erasca, Inc. (NASDAQ:ERAS) increased significantly by 30.0% in January, reaching 26,637,035 shares, which represents about 11.0% of the company's shares. Despite this rise in short interest, analysts maintain a "Moderate Buy" consensus rating with a target price of $9.22, and several firms have recently raised their price targets. Insider activity shows General Counsel Ebun Garner sold 120,000 shares in January, reducing her ownership by over 82%.
Assessing Erasca (ERAS) Valuation After A Powerful Share Price Run And High Price To Book Premium
Erasca (ERAS) has recently experienced a significant share price increase, with a 359.31% return over the past three months. Despite this strong performance, the company trades at a high Price-to-Book ratio of 9.4x, which is significantly above its biotech peers and the industry average, largely due to expectations for its oncology pipeline given zero revenue and ongoing losses. The article suggests that this premium valuation might be overlooking current financial realities and potential clinical setbacks.
Erasca stock hits 52-week high at $10.71 By Investing.com
Erasca Inc. (ERAS) stock reached a 52-week high of $10.71, driven by a 456.08% growth over the past year and a 656.12% surge in the last six months. This biotech company recently completed a public offering raising approximately $258.8 million and reported preliminary year-end cash of $341.8 million. Analysts have increased price targets, citing progress in cancer therapies, though the company is not expected to be profitable this year.
Erasca stock hits 52-week high at $10.71 By Investing.com
Erasca Inc. (ERAS) stock reached a 52-week high of $10.71, reflecting a 456.08% growth over the past year and 656.12% over six months, driven by investor optimism and progress in cancer therapies. Despite analysts forecasting unprofitability this year, the company recently completed a $258.8 million public offering and reported approximately $341.8 million in cash and securities. Analysts have raised price targets, citing advancements in Erasca's pan-RAS and pan-KRAS inhibitors and positive clinical updates.
Erasca stock hits 52-week high at $10.71
Erasca Inc. (ERAS) stock recently hit a 52-week high of $10.71, reflecting a significant milestone and investor optimism in the biotechnology company. The stock has seen remarkable growth, surging 456.08% over the past year and 656.12% in the last six months, despite analysts not expecting the company to be profitable this year. Recent developments include a successful public offering that raised $258.8 million and positive clinical updates for its ERAS-0015 drug, leading to increased price targets from analysts at Guggenheim and H.C. Wainwright.
Mizuho Initiates Erasca (ERAS) With 'Outperform' Rating and $16 PT
Mizuho initiated coverage of Erasca (ERAS) with an 'Outperform' rating and a $16 price target, reflecting confidence in its RAS inhibitor portfolio, particularly ERAS-0015. Guggenheim also raised its price target to $12 with a 'Buy' rating, and Morgan Stanley increased its price target to $10. These positive analyst reports followed Erasca's successful upsized public offering, which raised $258.8 million, and advancements in its precision oncology therapies.
Mizuho Initiates Erasca (ERAS) With ‘Outperform’ Rating and $16 PT
Mizuho initiated coverage of Erasca, Inc. (NASDAQ: ERAS) with an "Outperform" rating and a $16 price target, citing confidence in its RAS inhibitor portfolio's potential. Guggenheim also raised its price target to $12, reflecting positive updates on ERAS-0015 and ERAS-4001, and a recent financing round. Morgan Stanley similarly increased its price target to $10, maintaining an "Equal Weight" rating.
Mizuho Initiates Erasca (ERAS) With ‘Outperform’ Rating and $16 PT
Mizuho has initiated coverage on Erasca (ERAS) with an 'Outperform' rating and a $16 price target, signaling confidence in the company's RAS inhibitor portfolio. This follows other positive analyst actions, including Guggenheim raising its price target to $12 and Morgan Stanley increasing its target to $10. Erasca, which recently completed a significant public offering to raise $258.8 million, focuses on developing precision oncology therapies for RAS/MAPK-driven cancers.
11 Best Performing Stocks in the Last 12 Months
This article highlights Erasca, Inc. (NASDAQ: ERAS) as one of the best-performing stocks over the last 12 months, noting its 444.04% share performance. The company recently received strong analyst support, with Mizuho initiating coverage with an 'Outperform' rating and Guggenheim raising its price target, amidst progress in its RAS inhibitor portfolio and a significant public offering of its common stock. Erasca focuses on developing precision oncology therapies for RAS/MAPK-driven cancers.
Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models
Guggenheim has more than doubled its price target for Erasca (ERAS) to $12 following an update to its pipeline models and recent clinical progress, especially for ERAS-0015. This follows similar price target increases from Morgan Stanley and Piper Sandler, all citing promising early clinical data and revised valuation models for the precision oncology company. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers, with ERAS-0015 showing initial positive responses.
Does Erasca’s US$225 Million Equity Raise and ERAS-0015 Data Change The Bull Case For ERAS?
Erasca, Inc. recently completed a US$225 million equity offering, significantly bolstering its cash reserves and extending its funding runway for drug development. This capital raise, coupled with promising clinical data for ERAS-0015, strengthens the company's financial position as it advances its AURORAS-1 and BOREALIS-1 trials. However, the investment narrative still hinges on further clinical data, durability of benefit, and potential partnerships, with the company facing ongoing losses and a rich valuation.
Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models
Guggenheim has more than doubled its price target for Erasca (ERAS) to $12 from $5, maintaining a Buy rating, following clinical progress and updated pipeline models. This decision reflects risk-adjusted revenue estimates for ERAS-0015 and updated expectations for ERAS-4001. Other firms like Morgan Stanley and Piper Sandler also raised their price targets for Erasca based on promising early clinical data and refined valuation models.
Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models
Guggenheim raised its price target for Erasca (ERAS) to $12 from $5 with a Buy rating due to recent clinical developments and fresh financing. This follows similar increases from Morgan Stanley and Piper Sandler, who also raised their price targets based on promising clinical data for ERAS-0015 and updated valuation models. Erasca is a clinical-stage oncology company focused on RAS/MAPK pathway-driven cancers.
Does Erasca’s US$225 Million Equity Raise and ERAS-0015 Data Change The Bull Case For ERAS?
Erasca Inc. recently completed a US$225 million equity offering, significantly bolstering its cash position, which extends its funding runway for ERAS-0015 and ERAS-4001's clinical development. This capital raise, combined with encouraging early clinical data for ERAS-0015 showing partial responses without dose-limiting toxicities, reinforces the company's ability to finance its pipeline. Despite the strengthened balance sheet, the investment narrative still heavily relies on further positive clinical trial data, with the stock remaining sensitive to clinical headlines and investor sentiment.
Erasca extends cash runway after upsized public offering
Erasca, Inc. has extended its cash runway into the first half of 2029 following an upsized public offering that generated $242.7 million in net proceeds. This is in addition to its reported $341.8 million in cash and marketable securities as of December 31, 2025. Spark, TipRanks' AI Analyst, rates ERAS as Neutral, noting weak financial performance but acknowledging improved liquidity despite dilution.
Erasca, Inc. Closes Upsized Public Offering
Erasca, Inc. announced the successful closing of an upsized public offering on January 23, 2026, raising an estimated $242.7 million in net proceeds. This capital infusion, from the offering of 25,875,000 shares, is expected to finance the company's operations into the first half of 2029. The information is based on an SEC filing from January 29, 2026.
Does Erasca’s US$225 Million Equity Raise and ERAS-0015 Data Change The Bull Case For ERAS?
Erasca, Inc. recently completed a US$225 million equity offering, significantly bolstering its cash reserves. This capital raise, combined with promising clinical results for ERAS-0015, extends the company's financial runway and supports its development pipeline. While this strengthens Erasca's investment narrative, risks remain due to ongoing losses, no revenue, and a high valuation, with future catalysts depending on clinical data and potential partnerships.
Erasca, Inc. (ERAS) Stock Analysis: An Investor's Look At The 0.91% Potential Upside
Erasca, Inc. (ERAS) is a biotechnology company focused on precision oncology, with a market cap of $3.14 billion. Despite being in the clinical stage with negative EPS, it holds promising clinical developments, including naporafenib in Phase 3 trials and collaborations with major industry players. Analyst sentiment is cautiously optimistic, with an average target price suggesting a modest 0.91% upside, supported by technical indicators showing the stock might be oversold, yet acknowledging the inherent risks of biotech investments.
10 New Stocks on the Rise
This article lists "10 New Stocks on the Rise," focusing on Erasca Inc. (NASDAQ: ERAS) as a key example. It details recent analyst upgrades for Erasca, citing promising clinical trial data for its oncology drug candidates. The piece also mentions other rising stocks and subtly promotes Insider Monkey's AI stock picks.
Guggenheim raises Erasca stock price target to $12 on RAS inhibitor progress
Guggenheim has increased its price target for Erasca Inc. (NASDAQ:ERAS) to $12 from $5, maintaining a Buy rating, citing progress in the company's pan-RAS inhibitor ERAS-0015 and pan-KRAS inhibitor ERAS-4001 programs, along with recent financing. The biopharmaceutical company has seen significant stock momentum, and plans to present initial Phase 1 monotherapy data for ERAS-0015 in the first half of 2026. This positive outlook is also supported by strong financial metrics, including a high current ratio, despite some market analysis suggesting potential overvaluation.
Guggenheim raises Erasca stock price target to $12 on RAS inhibitor progress
Guggenheim has increased its price target for Erasca Inc. (NASDAQ:ERAS) to $12 from $5, maintaining a Buy rating, due to progress with its RAS inhibitors ERAS-0015 and ERAS-4001, and recent financing. Erasca has also reported strong preliminary year-end cash and securities, completed a significant public offering, and plans further clinical data presentations for its drug candidates in 2026. However, InvestingPro analysis suggests the stock might be overvalued despite its strong momentum and moderate debt levels.
Guggenheim raises Erasca stock price target to $12 on RAS inhibitor progress
Guggenheim has increased its price target for Erasca Inc (NASDAQ:ERAS) to $12 from $5, maintaining a Buy rating due to progress in its RAS inhibitor programs and recent financing. The company's stock has seen a significant 452% return over the past six months, reflecting investor optimism. Erasca is also planning to present initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 in 2026, alongside recent financial activities including a $258.8 million public offering and a strong current ratio.
Guggenheim raises Erasca stock price target to $12 on RAS inhibitor progress
Guggenheim increased its price target for Erasca Inc (NASDAQ:ERAS) to $12 from $5, maintaining a Buy rating, due to progress with its RAS inhibitors and recent financing. The company has shown significant stock momentum, and plans to release Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 in 2026. Erasca also reported strong preliminary year-end cash and completed a $258.8 million public offering.
Erasca stock price target raised to $15 from $11 at H.C. Wainwright
H.C. Wainwright has raised its price target for Erasca Inc (NASDAQ:ERAS) to $15.00 from $11.00, reiterating a Buy rating on the stock. This upgrade is based on positive clinical updates from the AURORAS-1 study of Erasca’s pan-RAS inhibitor, ERAS-0015, which has shown promising responses across various tumor types and RAS mutations. The drug has demonstrated linear pharmacokinetics and no dose-limiting toxicities, with clinical activity at low doses suggesting significant pathway suppression.
Morgan Stanley Raises Price Target on Erasca to $10 From $4, Keeps Equalweight Rating
Morgan Stanley has increased its price target for Erasca (ERAS) to $10 from $4, while maintaining an Equalweight rating on the stock. This adjustment comes as Erasca has recently closed a public offering and announced promising early clinical data for its ERAS-0015 compound. Erasca is a clinical-stage oncology company focused on therapies for RAS/MAPK pathway-driven cancers.
A Look At Erasca (ERAS) Valuation After Its Upsized Follow On Equity Offering
Erasca (ERAS) recently completed an upsized equity offering, raising US$225 million, which has significantly impacted its valuation. Despite strong recent share price performance and funding for R&D, the company's Price-to-Book ratio of 8.9x is considerably higher than the industry average, indicating potential overvaluation as it currently generates no revenue and incurs substantial losses. Investors are seemingly pricing in future pipeline success and management expertise rather than current financial metrics, highlighting the inherent risks in this early-stage biotech.
Erasca completes $258.8 million public offering of common stock By Investing.com
Erasca, Inc. has completed an upsized public offering of 25,875,000 shares of common stock at $10.00 per share, generating approximately $258.8 million in gross proceeds. The company plans to use these funds for research and development of its precision oncology therapies and for general corporate purposes. This capital raise bolsters Erasca's financial position, which is already strong with more cash than debt.
Erasca completes $258.8 million public offering of common stock By Investing.com
Erasca, Inc. has successfully closed an upsized public offering of 25,875,000 shares of common stock at $10.00 per share, raising approximately $258.8 million in gross proceeds. The clinical-stage precision oncology company, focused on RAS/MAPK pathway-driven cancers, plans to use these funds for research and development, as well as general corporate purposes. This capital raise significantly strengthens Erasca's financial position, as it reportedly holds more cash than debt.
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Erasca, Inc. has announced the closing of its upsized public offering of common stock, which included the full exercise of the underwriters' option to purchase additional shares. The company sold 25,875,000 shares at $10.00 per share, generating approximately $258.8 million in gross proceeds. Erasca intends to use these net proceeds, along with existing funds, to advance its research and development programs and for general corporate purposes.
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Erasca, Inc. has successfully closed its upsized public offering, selling 25,875,000 shares of common stock at $10.00 per share, which generated approximately $258.8 million in gross proceeds. This figure includes the full exercise of the underwriters' option to purchase additional shares. The company plans to use these net proceeds, along with existing funds, for research and development of its product candidates and for general corporate purposes.
Erasca stock hits 52-week high at 10.46 USD By Investing.com
Erasca Inc.'s stock has reached a 52-week high of $10.46, marking a 405.03% increase over the past year due to investor confidence in its oncology treatments and strategic partnerships. The company recently announced a proposed $150 million public offering of common stock and reported preliminary year-end cash and securities of approximately $341.8 million. Analysts at H.C. Wainwright and Stifel raised their price targets for Erasca based on promising clinical data for its ERAS-0015 degrader and positive pipeline updates.
Erasca, Inc. Announces Upsized Public Offering of Common Stock
Erasca, Inc. announced an upsized public offering of 22,500,000 shares of common stock at $10.00 per share, aiming to raise $225 million gross. The net proceeds of $211 million (or $242.7 million if the underwriters' option is fully exercised) are intended for research and development, product development, and general corporate purposes. The offering is expected to close on January 23, 2026.
Erasca Announces Major Underwritten Public Equity Offering
Erasca has priced a public offering of 22.5 million shares at $10.00 each, expected to generate approximately $211 million in net proceeds, or up to $242.7 million if underwriters fully exercise their option. This capital raise, supported by multiple underwriters, will fund research and development for its oncology product candidates and other corporate purposes, reinforcing its efforts in precision oncology. Spark, TipRanks’ AI Analyst, rates ERAS as Neutral, noting strong technicals but weak financials and potential near-term risks due to overbought signals.
Latham & Watkins Advises Erasca in Upsized US$225 Million Offering of Common Stock
Latham & Watkins advised Erasca, Inc. in its upsized public offering of 22,500,000 shares of common stock at US$10 per share, raising an expected US$225 million. Erasca, a clinical-stage precision oncology company, also granted underwriters a 30-day option to purchase additional shares. The offering is anticipated to close on January 23, 2026.
Top 2 Tech Stocks That Are Ticking Portfolio Bombs
This article identifies two tech stocks, RF Industries (RFIL) and Ultra Clean Holdings (UCTT), that are considered "overbought" based on their Relative Strength Index (RSI) values exceeding 70. RF Industries recently reported strong Q4 financial results, leading to an 82% stock gain in five days. Ultra Clean Holdings received an upgraded price target from an analyst and saw an 82% stock gain over the past month.
Erasca stock hits 52-week high at 10.46 USD
Erasca Inc. (ERAS) stock reached a new 52-week high of $10.46, reflecting a 405.03% increase over the past year, driven by investor confidence in its precision oncology treatments. The company recently announced a proposed $150 million public offering to raise capital and reported preliminary year-end cash and securities of approximately $341.8 million. Analysts at H.C. Wainwright and Stifel raised their price targets for Erasca based on promising clinical data for its ERAS-0015 molecular glue degrader and positive pipeline updates.
Erasca, Inc. Announces Pricing of $225 Million Public Offering of Common Stock
Erasca, Inc. has priced an upsized public offering of 22.5 million shares of its common stock at $10.00 per share, aiming to raise $225 million for research and development and general corporate purposes. The offering, expected to close on January 23, 2026, includes an option for underwriters to purchase an additional 3.375 million shares. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are managing the offering for the clinical-stage precision oncology company.
Erasca Announces Pricing of Upsized Public Offering of Common Stock
Erasca, Inc. has announced the pricing of an upsized public offering of 22,500,000 shares of its common stock at $10.00 per share, expecting gross proceeds of $225.0 million. The company, a clinical-stage precision oncology firm, plans to use these proceeds, along with existing cash, to fund research and development of its product candidates and other general corporate purposes. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering, which is anticipated to close on January 23, 2026.
Cancer drug developer Erasca raises $225M in stock sale
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, announced the pricing of an upsized public offering of 22,500,000 shares of its common stock at $10.00 per share, expecting to generate gross proceeds of $225.0 million. The company has granted underwriters a 30-day option to purchase an additional 3,375,000 shares. The net proceeds are intended to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes.
Erasca plans to raise $150 million in public stock offering By Investing.com
Erasca, Inc. announced its intention for an underwritten public offering to raise $150 million through the sale of common stock shares, with an option for underwriters to purchase an additional $22.5 million. The oncology company plans to use the net proceeds, along with existing funds, to advance its research and development of product candidates for RAS/MAPK pathway-driven cancers, as well as for general corporate purposes. This follows recent positive analyst updates and clinical trial data for its experimental pan-RAS molecular glue, ERAS-0015.
